CareDx Receives a Hold from H.C. Wainwright


H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on CareDx (NASDAQ: CDNA) today and set a price target of $15. The company’s shares closed yesterday at $12.01.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -1.9% and a 38.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on CareDx is a Moderate Buy with an average price target of $15.

See today’s analyst top recommended stocks >>

Based on CareDx’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.97 million. In comparison, last year the company had a GAAP net loss of $5.56 million.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDNA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts